The Wall Street Journal analyses the survival of Merck & Co. at the time when it is gradually losing its exclusive rights to several of its best-selling drugs. The story finds that the key for Merck's success is "searching for blockbuster drugs," instead of joining "the merger rush sweeping the pharmaceuticals industry." The reporter looks at the Merck's innovative research for painkilling drugs, and describes the effectiveness and the flaws of some of the company's new pills.
This file is not available for digital download. IRE members may place an order by emailing firstname.lastname@example.org